ImmuneRegen BioSciences'(R) Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant
14 Dicembre 2009 - 2:00PM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced that
treatment with its lead compound, Homspera, revealed that Homspera
improved the efficacy of a novel cancer vaccine which significantly
reduced tumor growth and greatly improved long-term survival in an
animal model of skin cancer. These are the latest findings
supporting the vaccine adjuvant capability of Homspera, and extend
to the cancer vaccine space in addition to previously shown
efficacy of Homspera in infectious disease models such as
influenza.
The study was performed at the University of Pittsburgh under
the guidance of Dr. Adriana Larregina, Research Assistant Professor
in the departments of Dermatology and Immunology at the University
of Pittsburgh School of Medicine. The results of the study showed
Homspera augmented a poorly effective vaccine against melanoma, the
deadliest form of skin cancer, into a highly effective vaccine. The
addition of Homspera as an adjuvant to this vaccine resulted in an
increased immune response, significantly (p <
0.01) reducing the size of tumors by approximately 85% after 3
weeks, and increasing the percentage of animals surviving from 0%
to 50% after 100 days (the end of the study period). Enhanced
immune responses, specifically the cellular immune component, could
be critical to the successful prevention and/or treatment of most
cancers. Since the completion of the studies Dr. Larregina has
joined ImmuneRegen's Scientific Advisory Board.
ImmuneRegen's Chief Scientific Officer, Hal Siegel, Ph.D.,
noted, "We have previously shown a wide range of activity for
Homspera, from human hematopoietic stem cell activation and
maturation, to acceleration of wound healing, stand-alone treatment
of pandemic influenza infection and vaccine adjuvant activity. A
common thread in our studies is the stimulation of immune cell
function. In light of the prior results from Dr. Larregina's lab on
dendritic cell stimulation and enhanced immune response following
Homspera, these tumor-directed activities provide a strong basis to
look in humans at the impact of Homspera on immune function and
perhaps cancer suppression. Our focus is now on proceeding to the
clinic."
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult stem cell active
compound that in study results has been shown to regenerate and
strengthen the immune system and enhance wound healing. Homspera is
being developed for potential use against infectious diseases as a
stand-alone or combination therapy and as a vaccine adjuvant. To
advance its mission, the Scottsdale, Arizona based company has
forged numerous study partnerships with industry and academic
leaders, including Celgene Cellular Therapeutics, HemoGenix,
Lovelace Respiratory Research Institute and Virion Systems. For
more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-KSB for the year ended December 31, 2008 as filed
with the Securities and Exchange Commission. There are no
guarantees that any of ImmuneRegen's proposed products will prove
to be commercially successful. ImmuneRegen undertakes no duty to
update forward-looking statements.
Contact: Michael K. Wilhelm OR John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact Email:
Email Contact
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni IR BioSciences (CE) (USOTC:IRBS)
Storico
Da Set 2023 a Set 2024